tetano
Editor, Senior Moderator
PLoS One
. 2023 Aug 22;18(8):e0290046.
doi: 10.1371/journal.pone.0290046. eCollection 2023. Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
Mafalda Cacciottolo[SUP] 1 [/SUP], Yujia Li[SUP] 1 [/SUP], Justin B Nice[SUP] 1 [/SUP], Michael J LeClaire[SUP] 1 [/SUP], Ryan Twaddle[SUP] 1 [/SUP], Ciana L Mora[SUP] 1 [/SUP], Stephanie Y Adachi[SUP] 1 [/SUP], Meredith Young[SUP] 1 [/SUP], Jenna Angeles[SUP] 1 [/SUP], Kristi Elliott[SUP] 1 [/SUP], Minghao Sun[SUP] 1 [/SUP]
Affiliations
Exosomes are emerging as potent and safe delivery carriers for use in vaccinology and therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to provide improved, broader, longer lasting neutralization of SARS-CoV-2, a more robust T cell response, enable widespread global usage, and further enhance the safety profile of vaccines given the likelihood of repeated booster vaccinations. Here, we use Capricor's StealthXTM platform to engineer exosomes to express native SARS-CoV-2 spike Delta variant (STX-S) protein on the surface for the delivery of a protein-based vaccine for immunization against SARS-CoV-2 infection. The STX-S vaccine induced a strong immunization with the production of a potent humoral immune response as demonstrated by high levels of neutralizing antibody not only against the delta SARS-CoV-2 virus but also two Omicron variants (BA.1 and BA.5), providing broader protection than current mRNA vaccines. Additionally, both CD4+ and CD8+ T cell responses were increased significantly after treatment. Quantification of spike protein by ELISA showed that only nanograms of protein were needed to induce a potent immune response. This is a significantly lower dose than traditional recombinant protein vaccines with no adjuvant required, which makes the StealthXTM exosome platform ideal for the development of multivalent vaccines with a better safety profile. Importantly, our exosome platform allows novel proteins, or variants in the case of SARS-CoV-2, to be engineered onto the surface of exosomes in a matter of weeks, comparable with mRNA vaccine technology, but without the cold storage requirements necessary for mRNA vaccines. The ability to utilize exosomes for cellular delivery of proteins, as demonstrated by STX-S, has enormous potential to revolutionize vaccinology by rapidly facilitating antigen presentation at an extremely low dose resulting in a potent, broad antibody response.
. 2023 Aug 22;18(8):e0290046.
doi: 10.1371/journal.pone.0290046. eCollection 2023. Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
Mafalda Cacciottolo[SUP] 1 [/SUP], Yujia Li[SUP] 1 [/SUP], Justin B Nice[SUP] 1 [/SUP], Michael J LeClaire[SUP] 1 [/SUP], Ryan Twaddle[SUP] 1 [/SUP], Ciana L Mora[SUP] 1 [/SUP], Stephanie Y Adachi[SUP] 1 [/SUP], Meredith Young[SUP] 1 [/SUP], Jenna Angeles[SUP] 1 [/SUP], Kristi Elliott[SUP] 1 [/SUP], Minghao Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 37607200
- DOI: 10.1371/journal.pone.0290046
Exosomes are emerging as potent and safe delivery carriers for use in vaccinology and therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to provide improved, broader, longer lasting neutralization of SARS-CoV-2, a more robust T cell response, enable widespread global usage, and further enhance the safety profile of vaccines given the likelihood of repeated booster vaccinations. Here, we use Capricor's StealthXTM platform to engineer exosomes to express native SARS-CoV-2 spike Delta variant (STX-S) protein on the surface for the delivery of a protein-based vaccine for immunization against SARS-CoV-2 infection. The STX-S vaccine induced a strong immunization with the production of a potent humoral immune response as demonstrated by high levels of neutralizing antibody not only against the delta SARS-CoV-2 virus but also two Omicron variants (BA.1 and BA.5), providing broader protection than current mRNA vaccines. Additionally, both CD4+ and CD8+ T cell responses were increased significantly after treatment. Quantification of spike protein by ELISA showed that only nanograms of protein were needed to induce a potent immune response. This is a significantly lower dose than traditional recombinant protein vaccines with no adjuvant required, which makes the StealthXTM exosome platform ideal for the development of multivalent vaccines with a better safety profile. Importantly, our exosome platform allows novel proteins, or variants in the case of SARS-CoV-2, to be engineered onto the surface of exosomes in a matter of weeks, comparable with mRNA vaccine technology, but without the cold storage requirements necessary for mRNA vaccines. The ability to utilize exosomes for cellular delivery of proteins, as demonstrated by STX-S, has enormous potential to revolutionize vaccinology by rapidly facilitating antigen presentation at an extremely low dose resulting in a potent, broad antibody response.